Skip to main content

Table 1 Patient baseline characteristics and transplant details

From: Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients

Total number of adult patients 39
Median (range) age (years) 35 (18–59)
Gender (%) 32 (82%) female
Disease subtype 39 (100%) diffuse
Median (range) disease duration (years)a 2 (0.5-14)
Organ involvement:
 Skin, n (%) 39/39 (100%)
 mRSS units, median (range) 24 (8–50)
 Interstitial lung disease, n (%) 28/39 (71.79%)
 Pulmonary hypertension, n (%) 3/39 (7.6 %) mild
 Forced vital capacity, % of predicted, mean (SD) 74.68 (32.5)
 Heart involvement, n (%)b 16/39 (40.9%)
 Esophageal dysmotility, n (%) 36/39 (92.30%)
 Kidney, n 0
 Positive anti-Scl-70 antibodies, n (%) 26/39 (66.6%)
Previous immunosuppressive treatment:
 Methotrexate, n (%) 17/39 (43.1 %)
 Cyclophosphamide, n (%) 29/39 (74.4 %)
 Mycophenolate mofetil, n (%) 8/39 (20.5 %)
 Rituximab, n (%) 2/39 (5.1 %)
Transplant regimen:
 Cyclophosphamide + ATG 36/39 (92.3%)
 Fludarabine + Melphalan + ATG 3/39 (7.7 %)
  1. Baseline (pre-transplant) clinical characteristics of patients enrolled in the study
  2. mRSS modified Rodnan Skin Score, IV intravenous infusion, ATG anti-thymocyte globulin
  3. aDisease duration from first non-Raynaud’s phenomenon clinical manifestation until transplant
  4. bPatients with severe heart involvement were excluded from transplant